MentalHealthDaily

Are Mystical Experiences Required for the Antidepressant Effects of Ketamine & Psychedelics?

by GLOOM

The intersection of mental health treatment and pharmacology is witnessing a remarkable shift with the growing interest in ketamine and classic psychedelics like psilocybin for their rapid and sustained antidepressant effects. Unlike traditional antidepressants, these substances offer hope for those with treatment-resistant depression by potentially transforming treatment paradigms. However, it remains somewhat unclear as to …

Tianeptine Trends in the U.S.: Antidepressant, Nootropic, Street Drug (“Gas Station Heroin” & ZaZa)

by GLOOM

Tianeptine is an atypical antidepressant that has been approved in several countries for treating depression but is not authorized for medical use in the United States. Despite this, it has found a significant market in the U.S. as a nootropic, often sold under names like ZaZa or Tianna Red, and has been nicknamed “gas station …

Ketamine Increases Amygdala Volume in Treatment-Resistant Depression (TRD) (2024 MRI Study)

by GLOOM

Depression is a complex mental health condition that significantly affects an individual’s emotional and physical well-being. Recent advances in neuroimaging have provided deeper insights into how major depressive disorder (MDD) alters brain structures, particularly the hippocampus and amygdala, and how treatments like ketamine can potentially reverse these changes. A new study using 3T and 7T …

Nortriptyline-Induced “Room Tilt Illusion”: A Rare Adverse Event of Antidepressants (2024 Case Report)

by GLOOM

Room Tilt Illusion (RTI) presents a perplexing challenge to both patients and physicians, transforming the familiar into the surreal as surroundings appear rotated or flipped. This rare condition, often linked to neurological or vestibular disorders, has recently been observed as an adverse effect of the antidepressant nortriptyline, used in treatment-resistant depression. A case report highlights …

Empagliflozin for Depression: Effective Adjunct with SSRIs (2024 Clinical Trial)

by GLOOM

Major Depressive Disorder (MDD) impacts millions globally, making it a significant public health challenge. Traditional treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) don’t work for everyone, highlighting the need for innovative approaches. Recent clinical trials exploring the use of empagliflozin, a medication originally used to lower blood sugar in diabetes patients, have shown promising results …

EPA & DHA Treat Depression in Mouse Models of Ulcerative Colitis (UC) (2024 Study)

by GLOOM

Recent research has uncovered significant insights into the intersection of physical and mental health, particularly focusing on the relationship between ulcerative colitis (UC) and depression. This study has delved into how two omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can alleviate depressive-like behavior in mice induced by UC. Through meticulous experimentation, it …

Black Seed Oil (Nigella Sativa) Effectively Reverses Antibiotic-Induced Depression in Mice (2024 Study)

by GLOOM

In a world increasingly reliant on antibiotics, emerging research sheds light on the unintended consequences of their chronic use, revealing significant impairments in mitochondrial function, hypothalamus-mediated metabolic operations, and amygdala-regulated emotional processes. A novel study has explored the potential of black seed oil (Nigella sativa oil, NSO) to mitigate these adverse effects, focusing on its …